Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AstraZeneca PLC stock logo
AZN
AstraZeneca
$76.62
-2.4%
$72.27
$60.47
$79.36
$237.56B0.476.02 million shs4.20 million shs
GSK plc stock logo
GSK
GSK
$44.25
-2.0%
$42.63
$33.33
$45.92
$91.70B0.653.53 million shs2.65 million shs
Haleon plc stock logo
HLN
Haleon
$8.40
+0.2%
$8.33
$7.70
$8.96
$38.36B0.285.78 million shs3.08 million shs
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AstraZeneca PLC stock logo
AZN
AstraZeneca
-2.44%-3.23%+1.93%+17.25%+5.65%
GSK plc stock logo
GSK
GSK
-1.94%-0.48%+7.63%+4.47%+29.22%
Haleon plc stock logo
HLN
Haleon
+0.24%-1.41%-0.59%+4.15%+1.69%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.3658 of 5 stars
1.35.01.70.02.50.03.1
GSK plc stock logo
GSK
GSK
2.1388 of 5 stars
0.03.02.50.02.50.02.5
Haleon plc stock logo
HLN
Haleon
2.793 of 5 stars
0.05.02.50.01.90.02.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.57
Moderate Buy$82.007.02% Upside
GSK plc stock logo
GSK
GSK
2.40
HoldN/AN/A
Haleon plc stock logo
HLN
Haleon
2.75
Moderate BuyN/AN/A

Current Analyst Ratings

Latest AZN, GSK, DPH, and HLN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/26/2024
AstraZeneca PLC stock logo
AZN
AstraZeneca
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$80.00 ➝ $82.00
4/17/2024
Haleon plc stock logo
HLN
Haleon
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
4/16/2024
AstraZeneca PLC stock logo
AZN
AstraZeneca
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Hold
3/26/2024
Haleon plc stock logo
HLN
Haleon
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/4/2024
GSK plc stock logo
GSK
GSK
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy
(Data available from 5/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AstraZeneca PLC stock logo
AZN
AstraZeneca
$45.81B5.19$5.27 per share14.55$12.63 per share6.07
GSK plc stock logo
GSK
GSK
$37.71B2.43$5.09 per share8.70$7.74 per share5.72
Haleon plc stock logo
HLN
Haleon
$14.05B2.73$0.37 per share22.91$4.51 per share1.86

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AstraZeneca PLC stock logo
AZN
AstraZeneca
$5.96B$2.0437.5616.411.4113.30%30.42%11.62%7/26/2024 (Estimated)
GSK plc stock logo
GSK
GSK
$6.13B$2.7616.039.811.3614.62%51.54%11.01%7/24/2024 (Estimated)
Haleon plc stock logo
HLN
Haleon
$1.30B$0.3028.0016.472.229.68%13.17%6.43%8/7/2024 (Estimated)

Latest AZN, GSK, DPH, and HLN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024Q1 2024
GSK plc stock logo
GSK
GSK
$0.94$1.09+$0.15$1.53$8.98 billion$9.34 billion
5/1/2024Q1 2024
Haleon plc stock logo
HLN
Haleon
$0.11$0.12+$0.01$0.12$3.71 billion$3.70 billion
4/25/2024Q1 2024
AstraZeneca PLC stock logo
AZN
AstraZeneca
$0.95$1.03+$0.08$1.36$11.92 billion$12.68 billion

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.932.52%+1.18%94.61%1 Years
GSK plc stock logo
GSK
GSK
$1.473.32%-18.18%53.26%N/A
Haleon plc stock logo
HLN
Haleon
$0.212.50%N/A70.00%1 Years

Latest AZN, GSK, DPH, and HLN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/1/2024
GSK plc stock logo
GSK
GSK
quarterly$0.37623.2%5/16/20245/17/20247/11/2024
2/29/2024
Haleon plc stock logo
HLN
Haleon
semi-annual$0.10641.8%3/14/20243/15/20245/16/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.73
0.89
0.70
GSK plc stock logo
GSK
GSK
1.15
0.87
0.58
Haleon plc stock logo
HLN
Haleon
0.53
1.04
0.73

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AstraZeneca PLC stock logo
AZN
AstraZeneca
20.35%
GSK plc stock logo
GSK
GSK
15.74%
Haleon plc stock logo
HLN
Haleon
6.67%

Insider Ownership

CompanyInsider Ownership
AstraZeneca PLC stock logo
AZN
AstraZeneca
N/A
GSK plc stock logo
GSK
GSK
10.00%
Haleon plc stock logo
HLN
Haleon
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AstraZeneca PLC stock logo
AZN
AstraZeneca
89,9003.10 billionN/AOptionable
GSK plc stock logo
GSK
GSK
70,2002.07 billion1.87 billionOptionable
Haleon plc stock logo
HLN
Haleon
25,4084.57 billionN/ANot Optionable

AZN, GSK, DPH, and HLN Headlines

Recent News About These Companies

Haleon (NYSE:HLN) Sees Strong Trading Volume
GSK confirms exit of Haleon stake for £3.9 billion
Haleon faces first short seller in Marshall Wallace
Sales Call
Haleon shares slide as revenue declines
Haleon revenues fall in first quarter
Haleon revenues fall in first quarter
Haleon plc (NYSE:HLN) Short Interest Update

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

AstraZeneca logo

AstraZeneca

NASDAQ:AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
GSK logo

GSK

NYSE:GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Haleon logo

Haleon

NYSE:HLN
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.